Available Online at

http://www.ijcpa.in

International Journal of CHEMICAL AND PHARMACEUTICAL ANALYSIS

October-December 2022

eISSN: 2348-0726 ; pISSN : 2395-2466

DOI:10.21276/2395-2466.22.10.085

Opinion Article | Volume-10 | Issue-4 | Article ID: 085

APPLICATION OF NEXETOL FOR HIGH RISK OF CHOLESTEROL

Joana Calivera*

Department of Drug Sciences, University of Porto, Porto, Portugal

***Corresponding Author:** *Email: calivera_juana@gmail.com*

Received: 01-Sep-2022, Manuscript No. IJCPA-22-77538; **Editor assigned:** 05-Sep-2022, PreQc No. IJCPA-22-77538 (PQ); **Reviewed:** 20-Sep-2022, QC No.IJCPA-22-77538; **Revised:** 27-Sep-2022, Manuscript No. IJCPA-22-77538(R); **Published:** 04-Oct-2022;DOI:10.21276/2395-2466.22.10.085

DESCRIPTION

Current cholesterol treatments focus more on developing novel ways to combine existing cholesterol medications and tailoring care to the patient. Giving everyone a statin right away is not merely standardised. Targeting medicines that are better for the elderly, those that are better for cancer patients, and similar topics are the focus of recent study.

A brand-new medication called Nexletol is prescribed for those who are at the greatest risk. That includes those who have high cholesterol due to genetic or familial factors or who have heart disease and need to lower their cholesterol even further. Bempedoic acid is the name of it. It reduces the cholesterol that your liver produces.

Statins are unique because they work by inhibiting the liver's capacity to produce cholesterol, which lowers blood cholesterol levels. As a result, the liver is able to absorb more cholesterol from the blood, lowering cholesterol levels. Through the HMG receptor, they can lower Low-Density Lipoprotein (LDL). This enzyme helps the body break down cholesterol. However, Nexletol also slows down the liver's ability to produce cholesterol, albeit *via* a different enzyme on the ACL route.

The PCSK9 inhibitors are additional medications that have been developed in the last few years. These are excellent because, in contrast to statins, they work in a completely different manner to decrease cholesterol. They don't cause muscle pain. Additionally, they may not always cause liver damage. The only problem with a PCSK9 inhibitor is that it’s an injection. Fortunately, we only need to administer an injection to ourself every two weeks, making it rather infrequent. For patients who struggle to regulate their LDL, we have been utilising it much more frequently.

Additionally, it is highly beneficial for those with hereditary hypercholesterolemia. Because the body doesn't recycle LDL cholesterol properly due to this genetic condition, your blood levels will remain high unless you receive medication. FH results from

a mutation in one of the body's many genes. The LDL-receptor gene is often involved in locating and eliminating cholesterol from the body.

Before beginning LDL apheresis, when doctors filter your blood to remove LDL cholesterol, nexletol is also a good start. A statin is actually a more recent alternative. Its brand name is Livalo or pitavastatin. It lowers LDL and total cholesterol in the same way as all other statins but, for some reason, doesn't cause muscle pain. This statin has proven to be much more effective for many people than any other statin on the market. It reduces their LDL to the appropriate level.

CONCLUSION

If people adopt a healthy lifestyle that includes nutrition and exercise, they may often lower their bad cholesterol by 20 to 30 points on average. If they keep up their healthy lifestyle habits, they can frequently reduce the dose of their statin. And some people completely stop their cholesterol medications. One long-term effect, even when we no longer taking Nexletol, is augmented liver proteins. Specifically, this drug may increase proteins level that are produced by our liver called transaminases. Raised transaminases can often specify liver damage or that something may be wrong with our liver, but other times it may not pointed anything.